Coronavirus: why antibody rates vary so widely from place to place
Tests show that likely levels of immunity range from 68% in parts of New York to less than 1% in India
Two-thirds of people in some New York communities have Covid-19 antibodies that are likely to provide some level of immunity to the virus, new research suggests.
The newly published data, from one of the companies involved in the US city’s testing programme, has renewed speculation about the reasons for huge variations in infection rates between countries, regions, cities and neighbourhoods.
In the aptly named district of Corona, “a working-class neighbourhood in Queens, more than 68% of people tested positive for antibodies to the new coronavirus”, The New York Times reports. “But at a clinic in Cobble Hill, a mostly white and wealthy neighborhood in Brooklyn, only 13% of people tested positive.”
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
How do the figures compare?
The worst-affected areas of New York “appear to show a higher antibody rate than anywhere in the world”, based on the new data, says The Telegraph.
However, the tests were not carried out on a random sample of the population but rather volunteers, who may have stepped forward precisely because they believed they had been exposed to the new coronavirus.
Nevertheless, parts of Italy have recorded similar results.
“More than half the residents tested in Italy’s northern province of Bergamo have Covid-19 antibodies,” Reuters reported in early June. The results were based on a random sample that researchers believe was “a reliable indicator of how many people had been infected in the province”.
In Spain, by contrast, a study conducted at around the same time found that just 5.2% of people had the antibodies. And nationwide testing in India discovered antibodies in only 0.73% of the population.
Meanwhile, a random testing programme by the UK Office for National Statistics found antibodies in 17.5% of Londoners. The figure fell to 10% in the east of England, 12% in the northwest, and between 4% and 8% in the rest of the country.
What lies behind the variations?
The main reason that antibodies are distributed so unequally is that the coronavirus pandemic has struck some areas far more acutely than others.
In Italy, for example, the north and east of the country suffered one of the world’s worst outbreaks, while the southern half of the country was largely unaffected.
Chance may have played a part in where the infection took hold, but how quickly the outbreaks spread is likely to have been influenced by living conditions, transport networks and government policies.
“There are reasons parts of Queens were hit so hard,” says The New York Times. “Homes in Elmhurst and parts of Corona are especially crowded,” which led to higher rates of transmission among family members, a “leading driver of the disease’s spread”.
What does this mean for herd immunity?
Since the beginning of the global pandemic, experts have voiced scepticism about hopes of ending the pandemic by achieving herd immunity. Proponents of the approach claim that once between 60% and 70% of a population has had the new coronavirus, the infection will no longer be able to spread.
But while “previous research into other coronaviruses has indicated that antibodies confer immunity”, scientists have not established beyond doubt that the same applies with Covid-19, says CNBC.
“The accuracy of the antibody tests is not fully known,” adds The New York Times. “Nor is the extent of immunity conferred by antibodies or how long that immunity lasts.”
If antibodies are short-lived or offer less-than-total protection, testing for their presence may lead researchers to overstate levels of immunity in the worst-hit areas.
However, some scientists believe antibody tests alone may underestimate how many people have at least partial protection against Covid-19.
Studies in Sweden and Germany have found that large numbers of people with no antibodies specific to the new coronavirus still have some level of immune response, perhaps as a result of their bodies having previously tackled other types of infections.
Trials are also under way to determine whether the BCG vaccination may prime the immune system to fight off the virus currently sweeping across the world.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
Today's political cartoons - December 21, 2024
Cartoons Saturday's cartoons - losing it, pedal to the metal, and more
By The Week US Published
-
Three fun, festive activities to make the magic happen this Christmas Day
Inspire your children to help set the table, stage a pantomime and write thank-you letters this Christmas!
By The Week Junior Published
-
The best books of 2024 to give this Christmas
The Week Recommends From Percival Everett to Rachel Clarke these are the critics' favourite books from 2024
By The Week UK Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
Deadly 'brain-eating' amoebas could be spreading thanks to climate change
Under the Radar Naegleria fowleri causes rare and lethal infection, but recent uptick in cases suggests it is thriving in warming waters
By Harriet Marsden, The Week UK Last updated
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Last updated
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
India's toxic alcohol problem
Under the Radar Bootleggers add lethal methanol to illegal liquor to cheaply increase potency, leading to widespread casualties
By Harriet Marsden, The Week UK Published